Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | HRH2 | P25021 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481898 | 0.94 | PKM (0.48) | PKMALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL7299651 | 0.85 | GRM5 (0.41) | PKMALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL6474441 | 0.85 | POLB (0.52) | PKMALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL2526216 | 0.83 | ALDH1A1 (0.64) | PKMALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL6474409 | 0.82 | ITGB3 (0.46) | PKMSMN1; SMN2ITGB3ITGA2BLMNA | |
| SCHEMBL7300441 | 0.80 | GRM5 (0.40) | PKMALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL6474034 | 0.79 | POLB (0.50) | PKMALDH1A1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL7678810 | 0.77 | SMN1; SMN2 (0.44) | PKMSMN1; SMN2ITGB3ITGA2BLMNA | |
| SCHEMBL6480916 | 0.77 | ITGB3 (0.47) | SMN1; SMN2ITGB3ITGA2BLMNA | |
| SCHEMBL7304398 | 0.77 | ITGB3 (0.38) | PKMALDH1A1CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867208-B2 | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | GENENTECH, INC. AND HOECHST AKTIENGESELLSCHAFT | 2003-02-06 | — | — | US | disclosed |
| US-6387895-B1 | BONE DISORDERS; CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6207663-B1 | AS INHIBITORS OF BONE RESORPTION, TUMOR GROWTH, TUMOR METASTASIS, OR INFLAMMATION, OR FOR THE TREATMENT OR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS, NEPHROPATHIES OR RETINOPATHIES | HOECHST ATKIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6011045-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | ADGRF1, ADGRE5, BSG | PKM 4641/4885ALDH1A1 3286/4885CYP1A2 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.